TY - JOUR
T1 - Liver follicular helper T-cells predict the achievement of virological response following interferon-based treatment in HCV-infected patients
AU - Tripodo, Claudio
AU - Petta, Salvatore
AU - Guarnotta, Carla
AU - Pipitone, Rosaria
AU - Cabibi, Daniela
AU - Colombo, Mario P.
AU - Craxi, Antonio
PY - 2012
Y1 - 2012
N2 - Background: Here, we assessed the presence of intrahepatic follicular helper T-cells (TFH) in a cohort of consecutive genotype 1 (G1) chronic hepatitis C (CHC) patients comprising non-responders (NRs), relapsers (RRs) or those with sustained virological response (SVR) to pegylated interferon and ribavirin, and tested their relation with the response to antiviral treatment. Methods: A total of 78 patients with G1 CHC (30 SVR, 15 RR and 33 NR), comparable for sex, age, viral load and fibrosis were evaluated by immunohistochemistry for liver content of PD1+Bcl6+ TFH cells. The number of TFHcells in the immunostained sections was counted out of five representative high-power microscopic fields (400x) relative to areas involved by the inflammatory infiltrate. IL28B rs12979860 and rs8099917 polymorphisms were also evaluated. Results: The absolute number of liver T FH progressively increased from NR to RR to a maximum in SVR patients (14.2 ±12.5 versus 24.5 ±12.5 versus 59.2 ±27.1; PFH was 24.3 ±21.1 in 18 TT polymorphism patients, 31.7 ±29.5 in 43 TC and 47.8 ±27.8 in 17 CC (P=0.01). SVR was achieved in 27/35 (77.1%) of patients with TFH≥28 and in only 3/43 (6.9%) of those with T FHFH at the threshold of 28 and the rs12979860 polymorphism, the ability to predict SVR strongly increased. Conclusions: In G1 CHC patients, TFH cells are present in the hepatic inflammatory infiltrate. Their amount is proportional to the ultimate likelihood of SVR, with a progressive increase from NR to RR to SVR. Quantification of TFH cells in the liver biopsy of these patients adds useful prognostic information.
AB - Background: Here, we assessed the presence of intrahepatic follicular helper T-cells (TFH) in a cohort of consecutive genotype 1 (G1) chronic hepatitis C (CHC) patients comprising non-responders (NRs), relapsers (RRs) or those with sustained virological response (SVR) to pegylated interferon and ribavirin, and tested their relation with the response to antiviral treatment. Methods: A total of 78 patients with G1 CHC (30 SVR, 15 RR and 33 NR), comparable for sex, age, viral load and fibrosis were evaluated by immunohistochemistry for liver content of PD1+Bcl6+ TFH cells. The number of TFHcells in the immunostained sections was counted out of five representative high-power microscopic fields (400x) relative to areas involved by the inflammatory infiltrate. IL28B rs12979860 and rs8099917 polymorphisms were also evaluated. Results: The absolute number of liver T FH progressively increased from NR to RR to a maximum in SVR patients (14.2 ±12.5 versus 24.5 ±12.5 versus 59.2 ±27.1; PFH was 24.3 ±21.1 in 18 TT polymorphism patients, 31.7 ±29.5 in 43 TC and 47.8 ±27.8 in 17 CC (P=0.01). SVR was achieved in 27/35 (77.1%) of patients with TFH≥28 and in only 3/43 (6.9%) of those with T FHFH at the threshold of 28 and the rs12979860 polymorphism, the ability to predict SVR strongly increased. Conclusions: In G1 CHC patients, TFH cells are present in the hepatic inflammatory infiltrate. Their amount is proportional to the ultimate likelihood of SVR, with a progressive increase from NR to RR to SVR. Quantification of TFH cells in the liver biopsy of these patients adds useful prognostic information.
UR - http://www.scopus.com/inward/record.url?scp=84856158421&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856158421&partnerID=8YFLogxK
U2 - 10.3851/IMP1957
DO - 10.3851/IMP1957
M3 - Article
C2 - 22267475
AN - SCOPUS:84856158421
VL - 17
SP - 111
EP - 118
JO - Antiviral Therapy
JF - Antiviral Therapy
SN - 1359-6535
IS - 1
ER -